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PURPOSE: To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with
efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC).
METHODS: We studied progression-free survival (PFS) in 91 ACC patients, of whom germ-line DNA was isolated and genotyped using an
Asper Biotech array. Overall survival (OS) and toxicity were studied as secondary end points. A step-wise selection of SNPs was
performed, involving univariate and multivariate log-rank tests and Cox regression analysis, with age and performance status as covariates.
RESULTS: A total of 81 SNPs in 46 genes on the array were selected for further analysis, based on genotyping success rates and minor allele
frequencies. After step-wise selection, we found that homozygosity for the ataxia telangiectasia mutated gene (ATM) rs1801516 or
excision repair cross-complementing gene (ERCC5) rs1047768 SNPs was associated with shorter PFS; however there were no significant
associations (P40.01) with OS or toxicity.
DISCUSSION: This is the first study describing the pathway gene approach for the selection of new candidate genes involved in oxaliplatin
efficacy and toxicity. The results suggest that the ATM and ERCC5 genes may be associated with oxaliplatin efficacy in ACC.
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Oxaliplatin is a cytotoxic anti-tumour agent that is frequently used
in advanced colorectal cancer (ACC; Punt, 2004). Its use results in
platination of (tumour) DNA and the formation of platinum/DNA
cross-links. Oxaliplatin adducts are lethal to cells, and may be
removed from the DNA through a number of DNA repair
pathways. Polymorphisms in the nucleotide excision repair
(NER), base excision repair (BER) and mismatch repair (MMR)
pathways were found to be associated with DNA repair after
oxaliplatin exposure (reviewed by Kweekel et al, 2005).
The classical way of studying associations between drug effects
and genetic variation is by the candidate gene method. This
method involves the careful selection of single nucleotide
polymorphisms (SNPs) based on the functionality of the genetic
variant. However, replication of associations as described in the
literature has not always been possible. For a large extent, this is
due to the fact that most drug effects are considered as complex
traits and are therefore not causally linked to one single gene or
SNP. An alternative to the candidate gene method is the whole-
genome approach (WGA). The main advantage of this method is
that it is hypothesis free because it does not rely on current
understanding of the pharmacokinetics and -dynamics of a drug.
However, false-positive results that occur from multiple testing are
a major concern in this type of research. The pathway gene method
is a combination of both methods; instead of candidate genes,
candidate pathways are selected based on the pharmacodynamic
and pharmacokinetic behaviour of a drug. After selecting the
appropriate pathways, SNPs in the corresponding genes are
included in association analysis. Compared to the WGA, the
pathway method involves a limited number of statistical associa-
tion tests while at the same time allowing a broader part of the
genome to be tested compared to the candidate gene method. The
risk of false-positive findings is lower compared to WGA; also,
because more enzymes in a pathway are studied, finding an
association with the most relevant gene is more likely (Wang et al,
2007). Asper Biotech offers DNA repair chips that determine 100
SNPs in 56 genes, including SNPs in the homologous repair
pathway, as well as SNPs in the BER, NER and MMR pathways.
Moreover, it bears SNPs from several genes related to the control
of cell-cycle and apoptosis pathways (including cyclin-dependent
kinases p16 and p21, and tumour suppressor protein p53; http://
www.asperbio.com/DNArepair.htm). These DNA repair chips are
promising means of investigating associations with response or
toxicity in patients receiving platinum derivatives, using the
pathway gene approach.
The purpose of the current study was to perform an explorative
association study of DNA repair pathway SNPs with progression-
free survival (PFS) in ACC patients receiving with oxaliplatin
combination therapy. Secondary end points were overall survival
(OS) and toxicity.
MATERIALS AND METHODS
Patients
Germ-line DNA was obtained from peripheral blood of Caucasian
patients with ACC who participated in the Dutch CAIRO trial. The
inclusion criteria and the clinical results of this study have been
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spublished elsewhere (Koopman et al, 2006). Patients were included
in the current side study if they were randomised to arm B
(combinational chemotherapy, starting with first-line irinotecan
plus capecitabine) and continued to second-line therapy, which
consisted of oxaliplatin (130mgm
 2 on day 1) and capecitabine
(1000mgm
 2, b.i.d. on days 1–14), every 3 weeks until progres-
sion or unacceptable toxicity. Dose reductions were performed for
capecitabine in case of grades 2–4 toxicity as described previously
(Van Cutsem et al, 2001). Oxaliplatin dose reductions of 25% were
carried out in case of grade 4 haematological toxicity, febrile
neutropenia and for persistent paresthesias (X14 days, grade 1
neurotoxicity) or temporary (7–14 days) painful paresthesias/
functional impairment (grades X2 neurotoxicity). Patients experi-
encing persistent grades X2 neurotoxicity received a 50%
oxaliplatin dose reduction. If haematological and non-haematolo-
gical toxicities had not recovered to grade 1 before the next
treatment cycle, oxaliplatin dose was delayed for a maximum of 2
weeks. If still not recovered by that time, patients went off-study.
Prophylactic use of haematological growth factors was not
permitted. The accrual period was from January 2003 to December
2004, and EDTA blood samples for genotyping were collected from
December 2003 to March 2005 after a protocol amendment. The
objective of this amendment was to perform genetic association
studies regarding drug efficacy and toxicity. The study protocol
and the amendment were approved by the local ethics committees.
Written informed consent was obtained from all patients
participating in the genetic association study before blood
collection. Tumour evaluation was performed every three cycles
according to RECIST criteria (Therasse et al, 2000) and toxicity
was graded according to US National Cancer Institute Common
Toxicity Criteria, version 2.0. The primary end point of this study
was association of individual SNPs with PFS. Secondary end points
were associations with OS and the incidence of overall worst
grades 3–4 toxicity. Progression-free survival was calculated as the
time from the start of second-line treatment with oxaliplatin to
progression, death or loss to follow-up, whichever came first.
Overall survival was also calculated as the time from the start of
second-line oxaliplatin treatment to death or loss to follow-up.
Progression-free survival was preferred as primary end point over
OS, because it reflects oxaliplatin efficacy and is not potentially
influenced by salvage therapies.
Genotyping
Peripheral EDTA blood was stored at  201C before isolation with
the Magnapure LC (Roche Diagnostics, Almere, the Netherlands)
according to the manufacturer’s instructions. Asper Biotech
(Tartu, Estonia) designed and performed a DNA repair chip
(including 100 DNA repair SNPs in 55 genes) according to
proprietary protocols. The chip contained SNPs of the following
pathways: BER (XRCC1, XRCC2, XRCC3, XRCC4, XRCC5, XRCC9,
APEX, POLB, LIG4, MYH, OGG1), NER (ERCC1, ERCC2, ERCC4,
ERCC5, LIG1, LIG3, RAD23B, XPA, XPC), MMR (MLH1, MSH2,
MSH3, MSH6, PMS2, RECQL), double-strand break repair and HR
(homologous recombination: BARD1, BRCA1, BRCA2, FANCD2,
NBS1, RAD51, RAD52, RAD54B, PARP1, PARP4), cell-cycle
regulation (ATM, CCND1, CCNH, CDKN1B, CDKN2B, CDK7,
CHEK2, RAD9A, TP53, TP53BP1, TP53BP2, p21, CDKN2A, GRTH,
GADD45A) and other enzymes involved in DNA synthesis (CDA,
NT5E, PCNA, MGMT).
As a quality control check, we compared the results of the Asper
Biotech array with six SNPs that had previously been determined
by our own laboratory in the same set of 91 DNA samples (Van der
Straaten et al, 2006) and unpublished data (available on request).
We found that, depending on the SNP, only 0.0–3.6% of the
samples showed results that were discordant, which suggests good
quality of the array and the procedures that were used in
genotyping. All genotype data are available on request.
Statistics
Patients randomised to the combination treatment who started
second-line oxaliplatin/capecitabine combination therapy and had
SNP assessment were eligible for the analysis (N¼91). A SNP was
considered evaluable for analysis if at least 90% of the patients
were successfully genotyped, and if the minor allele frequency
(MAF) was at least 5%.
Log-rank tests and Cox proportional hazards regression were
performed to investigate the association with PFS/OS. Logistic
regression analysis was performed to investigate the association
with toxicity. If more than three patients were homozygous for the
mutant allele, we tested both the separate genotypes individually
and the combination of genotypes using the dominant or recessive
model (carrier analysis). If three or less patients were homozygous
mutant, we only compared the wild-type patients with the mutant
allele carriers.
The purpose of this study was to explore the possible
associations of the clinical end points of each SNP, either as a
separate factor or combined. We used a two-step approach. In the
first step, we performed the univariate analysis of PFS, OS and
overall worst grades 3–4 toxicity for each SNP separately. Single
nucleotide polymorphisms with a P-value of o0.01 were
considered statistically significant and selected for the next step.
In the second step, a covariate analysis with age and a performance
status of 2 at the start of therapy (according to WHO guidelines)
was performed for each SNP separately. On the basis of previously
published results (Koopman et al, 2007), both a WHO perfor-
mance status of 2 and abnormal serum lactate dehydrogenase
(LDH) should ideally have been selected as covariates. However,
LDH was underreported in most patients at the start of second-line
treatment and therefore not used in the analysis. Age was selected
as a covariate because it generally associates with survival. Finally,
SNPs with a P-value of o0.01 were analysed in combination, in
one multivariate model with the same covariates as in the previous
step. This last analysis was performed for exploratory purposes
only, to evaluate the relative importance of the individual factors.
Correction for multiple testing was carried out. However, a
Bonferroni correction (based on the number of SNPs) would be far
too conservative in this case, because it assumes that the SNPs
investigated are all independent. Clearly, many of these SNPs are
not only in linkage disequilibrium but also the genes studied are
part of interacting pathways. Therefore, the only rational option to
correct for multiple testing is to account for the number of
pathways tested (in this case BER, NER, MMR, HR and cell-cycle
regulation, n¼5). One could argue that correcting for the number
of pathways even is too conservative, because these particular
pathways are not independent entities either (Curtis et al, 2005).
Moreover, a strict Bonferroni correction would negatively affect
the explorative nature of the study and would increase the chance
for false-negative results. For these reasons, we decided to set a at
0.01. Throughout the paper, we present unadjusted P-values.
RESULTS
A total of 91 patients were eligible for the current analysis. DNA
from these patients was genotyped using an SNP array with 100
SNPs on 55 genes. Two of these SNPs were excluded from analysis
because of low genotyping success rates (o90%). Seventeen SNPs
were excluded because of MAF o5%. The remaining 81 SNPs in 46
genes were used for analysis of PFS, OS and grades 3–4 toxicity.
All patients had genotype call rates exceeding 90%.
Step I: univariate analysis of oxaliplatin efficacy and
toxicity
Table 1 shows the SNPs for which the univariate analysis of PFS
and OS yielded log-rank P-values o0.05 (P for overall log rank).
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sAmong others, these include the genes ATM (ataxia telangiectasia
mutated gene, two SNPs), OGG1 (8-oxoguanine DNA glycosylase
gene), LIG4 (DNA ligase IV gene, two SNPs) and GADD45A
(growth arrest and DNA-damage-inducible gene a). The ATM,
GADD45A and OGG1 SNPs show (a trend towards) association
with both PFS and OS. On the basis of their P-values, we selected
Table 1 Step I: SNPs with Po0.05 in univariate analysis of PFS, OS and grades 3–4 toxicity
P*
PFS
ATM rs1801516 (Asp1853Asn)
Ataxia telangiectasia mutated gene
Regulator of tumour suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint
proteins RAD17 and RAD9 and DNA repair protein NBS1.
0.001
ERCC5 rs1047768 (T335C, His46His) Involved in excision repair of UV-induced DNA damage. 0.006
XPG, excision repair cross-complementing (5) gene
GADD45A rs532446 (T3812C)
Growth arrest and DNA-damage-inducible gene, a
The protein product of this gene responds to environmental stresses by mediating activation of the
p38/JNK pathway through MTK1/MEKK4 kinase.
0.008
RAD51 rs1801320 (G287C, Arg 96Pro) Involved in the homologous recombination and repair of DNA. 0.016
RecA homologue gene
ATM rs609429 (IVS48+238 C4G)
Ataxia telangiectasia mutated gene
Regulator of tumour suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint
proteins RAD17 and RAD9, and DNA repair protein NBS1.
0.024
OGG1 rs1052133 (Ser 326Cys)
8-Oxoguanine DNA glycosylase gene
Excision of 8-oxoguanine, a mutagenic base by-product that occurs as a result of exposure to
reactive oxygen.
0.025
BRCA2 rs15869 (105bp 30of STP A4C)
Breast cancer 2, early onset gene
Involved in maintenance of genome stability, specifically the homologous recombination pathway
for double-strand DNA repair.
0.033
OS
LIG4 rs1805388 ( 176 C4T, Thr 9Ile)
DNA ligase IV gene
DNA ligase that joins single-strand breaks through non-homologous end joining. This protein forms
a complex with the X-ray repair cross-complementing protein 4 (XRCC4).
0.008
BARD1 rs2070093 (His 506His) Forms a complex with BRCA1 that may be an essential aspect of tumour suppression by BRCA1. 0.009
BRCA1-associated RING domain 1 gene
OGG1 rs1052133 (Ser 326Cys)
8-Oxoguanine DNA glycosylase gene
Excision of 8-oxoguanine, a mutagenic base by-product that occurs as a result of exposure to
reactive oxygen.
0.015
GADD45A rs532446 (T3812C)
Growth arrest and DNA-damage-inducible gene, a
The protein product of this gene responds to environmental stresses by mediating activation of the
p38/JNK pathway through MTK1/MEKK4 kinase.
0.022
ATM rs609429 (IVS48+238 C4G)
Ataxia telangiectasia mutated gene
Regulator of tumour suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint
proteins RAD17 and RAD9, and DNA repair protein NBS1.
0.029
LIG4 rs1805389 ( 194 C4T)
DNA ligase IV gene
DNA ligase that joins single-strand breaks through non-homologous end joining. This protein forms
a complex with the X-ray repair cross-complementing protein 4 (XRCC4).
0.034
MUTYH rs3219489 (Gln 324His)
MUT Y homologue
Encodes a DNA glycosylase involved in oxidative DNA damage repair; excises adenine bases that
are inappropriately paired with, eg 8-oxo-7,8-dihydroguanine (major oxidative DNA damage).
0.049
XRCC1 rs25487 (G1301A, Arg 399Gln)
X-ray repair complementing defective repair (1)
Involved in the efficient repair of DNA single-strand breaks formed by exposure to ionizing
radiation and alkylating agents.
0.049
Toxicity
ERCC2 rs238406 (C499A, Arg156Arg)
XPD (excision repair cross-complementing rodent
repair deficiency, complementation group 2)
The protein encoded by this gene is involved in transcription-coupled nucleotide excision repair of
damaged DNA, and is an integral member of the basal transcription factor BTF2/TFIIH complex.
0.007
MGMT rs1803965 (C171T, Leu 53Leu) DNA repair gene regulated by p53, confers resistance to alkylating agents 0.016
O-6-methylguanine-DNA methyltransferase
MGMT rs12917 (C262T, Leu 84Phe) DNA repair gene regulated by p53, confers resistance to alkylating agents 0.023
O-6-methylguanine-DNA methyltransferase
LIG1 rs3730849 (IVS2+12 C4T)
DNA ligase I
LIG1 encodes DNA ligase I, with functions in DNA replication and the base excision repair process.
Mutations in LIG1 that lead to DNA ligase I deficiency result in immunodeficiency and increased
sensitivity to DNA-damaging agents.
0.031
SNPs with Po0.01 (in bold) were selected for further analysis. *P is the overall log-rank P-value. Rs numbers and functions are derived from the NCBI Entrez SNP database,
accessed December 2008 (http://www.ncbi.nlm.nih.gov/sites/entrez).
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(rs532446) SNPs for further analysis of PFS; the LIG4
(rs1805388) and BARD1 (rs2070093) SNPs were selected for
further analysis of OS.
With regard to overall toxicity grades 3–4, the genes O-6-
methylguanine-DNA methyltransferase (MGMT AGT, rs1803965
and rs12917) and ligase I (LIG1, rs3730849) showed P-values of
0.016, 0.023 and 0.031 respectively. ERCC2 (rs238406) was the only
SNP significantly associated with grades 3–4 toxicity (P¼0.007).
Carriers of the mutant allele showed a lower risk of developing
grades 3–4 toxicity. As only the ERCC2 SNP reached our criteria
for significance, it was selected for further analysis.
Step II: covariate analysis of oxaliplatin efficacy and
toxicity
We continued the analysis of SNPs selected in the first step by
individual multivariate analysis, using age and PS¼2 as covari-
ates. Genotype distributions of the selected SNPs are shown in
Table 2. For OS, neither LIG4 rs1805388 (P¼0.017) nor BARD1
rs2070093 (P¼0.094) reached significance when corrected for the
covariates. With regard to PFS however, we found that except for
GADD45A (rs532446), the remaining ATM (rs1801516) and ERCC5
(rs1047768) SNPs were significantly associated (Table 3). Homo-
zygote carriers of the ATM variant allele have a 4.25 times
increased risk (confidence interval, CI: 1.45–12.44) of progression
on second-line combination chemotherapy of capecitabine plus
oxaliplatin, compared to patients with the wild-type ATM
(P¼0.008). Patients homozygous for the ERCC5 (excision repair
cross-complementing gene, alternatively called XPG) variant allele
also show an increased risk of progression compared to wild-type
ERCC5 patients (HR for homozygote variant patients: 2.85; CI:
1.42–5.71, P¼0.003). Combined analysis of GADD45A (rs532446)
with the covariates suggested no relevant association of this SNP
with PFS (overall P for log-rank analysis: 0.216). To obtain
information on the relative impact on PFS of the ATM rs1801516
and ERCC5 rs1047768 SNPs, we performed a final multivariate
analysis of both SNPs combined, corrected for performance status
and age as covariates. We found that patients homozygous for the
variant allele of ATM rs1801516 had a 3.2 times increased risk of
progression (CI: 1.06–9.73, P¼0.039), whereas this risk was 2.4
times increased in patients homozygous for the ERCC5 rs1047768
variant allele (CI: 1.14–4.99, P¼0.021).
With regard to toxicity, we found that the association of the
ERCC2 rs238406 SNP was diminished to P¼0.018 after adjusting
for the covariates. Patients carrying X1 mutant ERCC2 allele have
a 0.28 times risk to experience grades 3–4 toxicity during
treatment with oxaliplatin (CI: 0.10–0.81).
DISCUSSION
This is the first study describing the pathway gene approach for
the selection of new candidate genes involved in oxaliplatin
efficacy and toxicity. The results of this analysis suggest that ATM
and ERCC5 might be involved in the efficacy of oxaliplatin-
containing chemotherapy for ACC. The current report, although
explorative in nature, may serve as a basis for further studies in
other patient populations.
The ATM gene product interacts with the ERCC5 protein, and
this complex prevents platinum-treatment-induced apoptosis
(Colton et al, 2006). Two genetic variations in the ATM gene have
already been studied in association with OS, including the intronic
G60A (rs664143) and the T-77C (rs664677) SNP. Pancreatic cancer
patients receiving gemcitabine and radiation with or without
combined gemcitabine/cisplatin induction therapy have shorter OS
Table 2 Genotype distributions of SNPs, selected by univariate analysis of PFS, OS and toxicity
SNP Wild type, N (%) Heterozygotes, N (%) Homozygote mutants, N (%) Total, N
ATM rs1801516 63 (69.2) 24 (26.4) 4 (4.4) 91
ERCC5 rs1047768 28 (30.8) 46 (50.5) 17 (18.7) 91
GADD45A rs532446 49 (55.1) 31 (34.8) 9 (10.1) 89
LIG4 rs1805388 62 (68.1) 27 (29.7) 2 (2.2) 91
BARD1 rs2070093 62 (68.1) 25 (27.5) 4 (4.4) 91
ERCC2 rs238406 27 (30.0) 46 (51.1) 17 (18.9) 90
Table 3 Step II: hazard ratios (CIs) of treatment outcome for colorectal cancer patients receiving oxaliplatin, after adjusting for covariates
Outcome
measure Polymorphism
Heterozygote vs
wild type
Homozygote
mutant vs wild type
Carrier
analysis Age
Performance
status
Overall
P
#
Progression-free survival ATM rs1801516 0.72 (0.43; 1.21) 4.25 (1.45; 12.44) 4.60 (1.58; 3.37) 0.98 (0.96; 1.01) 1.80 (0.71; 4.55) 0.009
P¼0.008 P¼0.005*
ERCC5 rs1047768 1.71 (0.98; 2.98) 2.85 (1.42; 5.71) 1.92 (1.13; 3.27) 0.98 (0.96; 1.00) 1.62 (0.63; 4.13) 0.012
P¼0.003 P¼0.016**
GADD45A rs532446 1.58 (0.95; 2.62) 1.14 (0.53; 2.46) 1.44 (1.04; 1.99) 0.98 (0.96; 1.00) 1.56 (0.60; 4.04) 0.216
P¼0.029**
Overall survival LIG4 rs1805388 — — 1.83 (1.11; 3.00) 0.98 (0.96; 1.01) 1.42 (0.50; 4.07) —
P¼0.017**
BARD1 rs2070093 1.81 (1.05; 3.12) 1.56 (0.56; 4.38) 1.76 (1.05; 2.95) 0.98 (0.96; 1.01) 1.38 (0.44; 3.50) 0.094
P¼0.034 P¼0.031**
Toxicity grade X3 ERCC2 rs238406 0.36 (0.12; 1.09) 0.10 (0.02; 0.62) 0.28 (0.10; 0.81) 3.07 (0.39; 24.29) 1.09 (1.02; 1.17) 0.028
P¼0.070 P¼0.013 P¼0.018** P¼0.008
#P overall log rank P-value; carrier analysis: *P wild-type and heterozygotes vs homozygote mutants; **P heterozygotes plus homozygote mutants vs wild-type patients;
performance status defined as stated in the Materials and methods section. All P-values in bold are significant according to the threshold set out in the Materials and methods
section; other P-values are shown for clarification of confidence intervals only. In the carrier analysis, the most appropriate model (recessive or dominant) was chosen for
combined analysis of genotypes, based on the individual HR of each category. Owing to the small number of LIG4 rs1805388 homozygote mutant patients, no log rank P-value
could be calculated to compare the 3 genotypes. SNPs with Po0.01 were selected for further analysis.
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sif they carry the  77C variant (Li et al, 2006). A longer OS was
reported in the same study population for patients who are
homozygous for the 60A allele (Okazaki et al, 2008). The ATM SNP
determined in the current study (rs1801516, or G5557A) has
recently been shown to have an association with a reduced risk of
breast cancer (Schrauder et al, 2008). This particular SNP is not in
linkage with the ATM SNPs T-77C and G60A (r
2¼0.22, based on
HapMap data phase II, March 2008). In the literature there are no
data on the functionality of the Asp to Asn amino-acid substitution
at this position. However, theoretically the substitution of the
negatively charged Asp to neutral Asn may influence the ATM’s
interaction with other proteins. This may be a likely explanation,
because the Asp amino acid at position 1853 appears to be highly
conserved trough evolution (Schrauder et al, 2008).
The other variant, ERCC5 (rs1047768, or T335C), has been studied
in ACC and ovarian cancer patients. A longer OS and PFS were
reported for homozygous wild-type ACC patients treated with
oxaliplatin/capecitabine combination therapy (Monzo et al, 2007),
and similarly, a shorter OS was reported for homozygous mutant
patients with ovarian cancer, treated with platinum-based che-
motherapy (Saldivar et al, 2007). Although the results of the current
study confirm these previous findings, it remains uncertain why a
synonymous or ‘silent’ SNP would have clinical impact as the amino-
acid sequence is unaltered. One explanation may be that this genetic
variant is in linkage with other SNPs that do influence the amino-acid
sequence of ERCC5. Alternatively, this silent ERCC5 SNP may result
in a different protein conformation and hence different substrate
specificity or enzyme activity, as was shown for several silent SNPs
such as SNPs in the gene encoding P-glycoprotein (Komar, 2007).
Some of the SNPs detected in the presently used array have
already been studied before by other groups, and we will
summarise their findings for comparison. Previous studies
included the SNPs ERCC1 rs11615 (C118T) and rs3212986
(C8092A), ERCC2 rs13181 (Lys751Gln) and rs238406 (C499A) as
well as XRCC1 rs25487 (Arg399Gln). Besides the latter, none of
these SNPs showed a (borderline) significant association with PFS
or OS in the current univariate analysis. Various studies in
colorectal cancer (Park et al, 2003; Stoehlmacher et al, 2004;
Viguier et al, 2005; Ruzzo et al, 2007) and lung cancer patients (Su
et al, 2007) suggest that the ERCC1 118CC genotype is associated
with longer OS and a better response towards platinum agents.
Another study reports no association of this SNP with OS (Zhou
et al, 2004), but a significantly worse OS was found for patients
carrying X1 mutant allele of the other ERCC1 SNP, C8092A. For
this SNP, an association with platinum-induced gastrointestinal
toxicity was found by others (Suk et al, 2005). Regarding ERCC2,
most of the research has focused on Lys751Gln. Some authors
report no association of this SNP with clinical outcome (Giachino
et al, 2007; Monzo et al, 2007) or toxicity (Le Morvan et al, 2007),
whereas others describe a better anti-tumour response (Park et al,
2001; Ruzzo et al, 2007), longer OS (Stoehlmacher et al, 2004) and
increased haematological toxicity (Booton et al, 2006) in wild-type
homozygotes. For the other ERCC2 SNP, C499A, no association
with OS or response has been reported (Park et al, 2001).
Furthermore, the current study shows a trend towards longer OS in
patients carrying X1 mutant allele of XRCC1 Arg399Gln, which is
in contrast to other studies reporting no association (Giachino
et al, 2007) or a shorter OS in patients with a mutant allele
(Gurubhagavatula et al, 2004).
A general problem of studies investigating a large set of SNPs is
the risk of false-positive findings; for this reason we set our
threshold for significance at a¼0.01. However, in this particular
case, our major concern is false-negative results due to the relatively
small sample size. This risk can only be minimised by using data
from more patients, which, in turn, is not always feasible due to
limited access to clinical data and patient samples. False-negative
results due to low power can explain the inability to replicate the
previously discussed associations found by other groups. However,
the inability to replicate may also reflect differences in patient
selection, publication bias, chance or low correlation of a marker
with the outcome measure (Colhoun et al, 2003). Another concern of
our study may be the low threshold that was set for the MAF (45%).
More specifically, it required that at least nine mutant alleles were
genotyped for the given sample set. As a result, the power to detect
associations with uncommon genetic variants was low. However, the
commercial array included many SNPs with low MAFs (e.g. 17 SNPs
were excluded because of MAFo5%). In our opinion, SNPs with low
MAF should preferably not be included when developing an array.
In the palliative treatment of ACC, much progress has been
made in recent years with the aid of pharmacogenetics. For
instance, studies have revealed that patients with mutated K-RAS
oncogene do not benefit from cetuximab treatment (Karapetis
et al, 2008). Febrile neutropenia, one of the side effects of
irinotecan, can be predicted by the uridine diphosphate glucur-
onosyl transferase (UGT)1A1 *28 genotype (Kweekel et al, 2008).
The results of the current study, although explorative in nature,
need to be confirmed in a larger, independent cohort and may
serve as a basis for new candidate SNP studies of genes located in
the various DNA repair pathways.
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